CEDRA Corporation Appoints Director of Automation for the Bioanalytical Group

AUSTIN, Texas--(BUSINESS WIRE)--CEDRA Corporation, a division of Worldwide Clinical Trials and provider of Phase I-IIb clinical research and bioanalytical services, announced today the appointment of Thomas L. Lloyd as Director of Automation for the Bioanalytical Group.

“Thomas is an enormous asset to the CEDRA team”

Lloyd has over 22 years of industry experience in successfully developing and automating analytical and bioanalytical processes. His specific expertise lies within the areas of automation systems and analytical instrument development, bioanalytical chemistry, in vitro DMPK studies, software programming and application, statistics, chemometrics and GLP requirements.

“Thomas is an enormous asset to the CEDRA team," stated CEDRA CEO, Anthony G. Busa, Jr. "His extensive industry experience and knowledge in developing and automating analytical and bioanalytical processes are energizing to our team, and his passion for excellence and superior client satisfaction are elevating our offerings to the next level. We are very excited to have him with us and are looking forward to his contributions.”

Lloyd received undergraduate degrees in chemistry and economics from Duke University, where he also earned a Master of Business Administration degree in operations management. He continues academic study and instrumentation training in robotics, electronics, drug metabolism, pharmacokinetics, computer programming and analytical and organic chemistry.

Prior to joining CEDRA, Lloyd led the automation group at Pfizer, previously known as Wyeth Research. He has held previous positions at DuPont Merck Pharmaceutical Company and Glaxo. Lloyd has an impressive list of publications, podium and poster presentations of which he has authored/co-authored and presented.

About CEDRA

CEDRA Corporation, a division of Worldwide Clinical Trials, offers a full range of Phase I-IIb clinical research and bioanalytical services, as well as specialized studies to the pharmaceutical/biotech and medical device industries. CEDRA’s combination of a state-of-the-art bioanalytical laboratory with clinical research sites allows them to play an important role in drug development programs. To learn more about CEDRA, visit www.cedracorp.com.